Literature DB >> 1184747

Biochemical determinants of 5-fluorouracil response in vivo. The role of deoxyuridylate pool expansion.

C E Myers, R C Young, B A Chabner.   

Abstract

5-Fluorodeoxyuridine monophosphate (FdUMP), the active metabolite of 5-fluorouracil (5-FU), is a tight-binding inhibitor of thymidylate synthetase, the enzyme which converts dUMP to TMP. Newly developed assays for FdUMP and dUMP were utilized to assess the competitive roles played by these nucleotides in determining the inhibition of TMP synthesis in mice bearing the P1534 ascites tumor. After 5-FU administration, levels of FdUMP reached a dose-dependent peak within 6 h in the ascites tumor and in bone marrow, and declined thereafter in a biphasic manner with an initial t 1/2 of 6 h and a final t 1/2 of 7-9 days. In duodenal mucosa, FdUMP levels were 1.8-2-fold higher than in the other tissues, but elimination was much more rapid. Simultaneous with the fall in FdUMP a progressive accumulation of the competitive substrate dUMP was observed in each tissue after 5-FU; and peak dUMP levels coincided with recovery of thymidylate synthesis, as determined by the incorporation of [3H]deoxyuridine into DNA. In vitro experiments with partially purifed thymidylate synthetase revealed and initial competitive interaction of dUMP and FdUMP, which, at high concentrations of dUMP was capable of markedly slowing the rate of irreversible inactivation of enzyme by FdUMP. These studies were found to be quantitatively consistent with a two-phase model of enzyme inactivation involving an initial competition between dUMP and FdUMP, with subsequent irreversible inactivation of enzyme by covalent linkage to the inhibitor. Recovery of thymidylate synthesis after 5-FU appears to result from both a fall in intracellular levels of inhibitor and a progressive accumulation of the competitive substrate dUMP.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1184747      PMCID: PMC301986          DOI: 10.1172/JCI108199

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

1.  Studies on fluorinated pyrimidines. V. Effects on nucleic acid metabolism in vitro.

Authors:  L BOSCH; E HARBERS; C HEIDELBERGER
Journal:  Cancer Res       Date:  1958-04       Impact factor: 12.701

2.  A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid.

Authors:  K BURTON
Journal:  Biochem J       Date:  1956-02       Impact factor: 3.857

3.  Thymidine incoporation into mammalian strain L-cells after the action of 5-fluorodoxyuridine and the effect of uracil.

Authors:  M Klímek
Journal:  Neoplasma       Date:  1965       Impact factor: 2.575

4.  Assay of 5-fluorodeoxyuridine 5'-monophosphate deoxyuridine 5'-monophosphate pools following 5-fluorouracil.

Authors:  C E Myers; R C Young; D G Johns; B A Chabner
Journal:  Cancer Res       Date:  1974-10       Impact factor: 12.701

5.  Inhibition of cytotoxic action of 1- -D-arabinofuranosylcytosine on S-phase HeLa cells by 5-fluorodeoxyuridine.

Authors:  R L Momparler
Journal:  Cancer Res       Date:  1973-07       Impact factor: 12.701

6.  Thymidylate synthetase: mechanism of inhibition by 5-fluoro-2'-deoxyuridylate.

Authors:  R J Langenbach; P V Danenberg; C Heidelberger
Journal:  Biochem Biophys Res Commun       Date:  1972-09-26       Impact factor: 3.575

7.  Nonenzymatic exchange of tritium from (5-3H) deoxyuridylate in the thymidylate synthetase assay.

Authors:  M Kawai; B L Hillcoat
Journal:  Anal Biochem       Date:  1974-04       Impact factor: 3.365

8.  The effect of chemotherapy on the kinetics and proliferative capacity of normal and tumorous tissues in vivo.

Authors:  S H Rosenoff; J M Bull; R C Young
Journal:  Blood       Date:  1975-01       Impact factor: 22.113

9.  Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate.

Authors:  D V Santi; C S McHenry; H Sommer
Journal:  Biochemistry       Date:  1974-01-29       Impact factor: 3.162

10.  Purification and amino acid analysis of an active site peptide from thymidylate synthetase containing covalently bound 5-fluoro-2'-deoxyuridylate and methylenetetrahydrofolate.

Authors:  H Sommer; D V Santi
Journal:  Biochem Biophys Res Commun       Date:  1974-04-08       Impact factor: 3.575

View more
  26 in total

1.  In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines.

Authors:  Y Sugimoto; Y Ohe; K Nishio; T Ohmori; Y Fujiwara; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  The practical benefits of pharmacokinetics in the use of antineoplastic agents.

Authors:  C Erlichman; R C Donehower; B A Chabner
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

Review 3.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

Review 4.  Pharmacogenomics in colorectal cancer: the first step for individualized-therapy.

Authors:  Eva Bandrés; Ruth Zárate; Natalia Ramirez; Ana Abajo; Nerea Bitarte; Jesus Garíia-Foncillas
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

Review 5.  Cellular pharmacology of fluorinated pyrimidines in vivo in man.

Authors:  J S Kovach; R W Beart
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

Review 6.  The fluoropyrimidines: biochemical mechanisms and design of clinical trials.

Authors:  M A Friedman; W Sadée
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

7.  Effect of concurrent calcium leucovorin infusion on 5-fluorouracil cytotoxicity against murine L1210 leukemia.

Authors:  P Klubes; I Cerna; M A Meldon
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

8.  5-fluorouracil-methotrexate synergy: enhancement of 5-fluorodeoxyridylate binding to thymidylate synthase by dihydropteroylpolyglutamates.

Authors:  D J Fernandes; J R Bertino
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

9.  Pharmacokinetics of 5-fluorouracil: inter-relationship with biochemical kinetics in monitoring therapy.

Authors:  W Sadee; C G Wong
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

10.  Kinetic behaviour and allosteric regulation of human deoxycytidylate deaminase derived from leukemic cells.

Authors:  P H Ellims; A Y Kao; B A Chabner
Journal:  Mol Cell Biochem       Date:  1983       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.